Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000824307 | SCV000965200 | uncertain significance | Rhabdoid tumor predisposition syndrome 2 | 2022-02-18 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C65"). ClinVar contains an entry for this variant (Variation ID: 665921). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 402 of the SMARCA4 protein (p.Ile402Thr). |
Ambry Genetics | RCV001010302 | SCV001170477 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-15 | criteria provided, single submitter | clinical testing | The p.I402T variant (also known as c.1205T>C), located in coding exon 6 of the SMARCA4 gene, results from a T to C substitution at nucleotide position 1205. The isoleucine at codon 402 is replaced by threonine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Genome- |
RCV001809848 | SCV002056428 | uncertain significance | Intellectual disability, autosomal dominant 16 | 2021-07-15 | criteria provided, single submitter | clinical testing |